SCHEMBL5333142

SCHEMBL5333142

CCN(Cc1ccccc1N1CCN(C(=O)OC(C)(C)C)CC1)S(C)(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.44
GAA P10253 1/20 0.44
CKS1B P61024 2/20 0.43
SKP1 P63208 2/20 0.43
SKP2 Q13309 2/20 0.43
KMT2A Q03164 2/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
GPR119 Q8TDV5 4/20 0.42
MC4R P32245 1/20 0.42
MEN1 O00255 1/20 0.42
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
ACHE P22303 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5335971 0.89 SMN1; SMN2 (0.53) SMN1; SMN2GAAKMT2AUSP2LMNA
SCHEMBL5343864 0.87 GPR119 (0.43) SMN1; SMN2GAACKS1BSKP1SKP2
SCHEMBL5334482 0.85 MC4R (0.49) SMN1; SMN2GAACKS1BSKP1SKP2
SCHEMBL14387781 0.85 MC4R (0.44) SMN1; SMN2GAACKS1BSKP1SKP2
SCHEMBL7981893 0.83 GAA (0.56) SMN1; SMN2GAACKS1BSKP1SKP2
SCHEMBL4511470 0.83 GPR119 (0.50) SMN1; SMN2GAACKS1BSKP1SKP2
SCHEMBL5333002 0.82 CKS1B (0.47) SMN1; SMN2GAACKS1BSKP1SKP2
SCHEMBL5335663 0.80 MC4R (0.55) SMN1; SMN2GAACKS1BSKP1SKP2
SCHEMBL14355807 0.80 DRD2 (0.49) GAAKMT2ALMNAMC4RMEN1
SCHEMBL5336420 0.80 MC4R (0.45) SMN1; SMN2GAACKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R SMN1; SMN2 1943/4885GAA 2665/4885CKS1B 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.